After severe psoriasis impacted her choice of clothing, relationships, and mood for many years, a 34-year-old female patient experiences skin clearance with SKYRIZI.

SKYRIZI allows an older male patient to regain optimism about achieving durable skin clearance after multiple unsuccessful treatments and 48 years of being affected by psoriasis.

Dr Keith Wu and Pauline Stopford- Taylor revisit their experience setting up a specialist service in York. They also illustrate the convenience in dosing and impact of SKYRIZI by sharing their treatment journey with a patient whose psoriasis of the hands was affecting his ability to act as a primary carer for his wife.

Due to his successful psoriasis treatment with SKYRIZI and its convenient administration, a 37-year-old male patient travels the world and undertakes an international work placement in New York.

A 53 year old male with comorbidities affected by chronic plaque psoriasis since 1981, achieves skin clearance with SKYRIZI and participates in activities such as photography, socialising, and walking.

After two years of unsuccessful treatment, a 29-year-old male patient switches to SKYRIZI, clears his facial and scalp psoriasis, and regains the confidence to play football with his friends.

SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.¹
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.¹
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]